Precision oncology has transformed cancer care, but its benefits remain unevenly distributed because of persistent gaps in resources and representation. Integrating multiomics data, clinical trial evidence, and real-world data enables the identification of both biological and extrinsic drivers of cancer inequities and can further advance treatment decisions across diverse populations worldwide.
Liu et al. (Wed,) studied this question.